December 5, 2022 – Solid Biosciences and AavantiBio merged to advance genetic medicines for neuromuscular and cardiac rare diseases.
AavantiBio was founded on deep scientific expertise in rare genetic disease research
We believe in the power the voice of the rare disease community has around the world. We at AavantiBio strive to empower that voice through science to ensure the patient story, insight, and perspective are the guiding principles behind everything we do
We are committed to standing alongside the rare disease community to empower patients and families through education, advocacy, resources, and engagement opportunities. This begins with dedicating our time to building strong partnerships with patients, their families, and the community